Assessment of Blood Indices in Systemic Lupus Erythematosus
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
Age18+
SponsorAssiut University
About this trial
This case-control study aims to explore the relationship between specific blood indices (lymphocyte-monocyte ratio, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and systemic immune-inflammatory index) and disease activity in patients with systemic lupus erythematosus (SLE).
The study includes 70 SLE patients and 70 healthy controls, matched for age and gender, recruited from Assiut University Hospital.
Disease activity is assessed using the SLEDAI-2K score, and blood indices are analyzed to determine correlations with disease activity.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Patients aged 18 years or older diagnosed with SLE according to the 2019 ACR/EULAR classification criteria.
Healthy controls without any autoimmune diseases or significant comorbidities
Disqualifiers
• Patients with other autoimmune diseases (e.g., rheumatoid arthritis, Sjögren's syndrome).
Recent infections or acute inflammatory conditions.
Individuals with hematological disorders unrelated to SLE (e.g., leukemia, lymphoma).
Trial population
cases are Patients aged 18 years or older diagnosed with SLE according to the 2019 ACR/EULAR classification criteria and • Healthy controls without any autoimmune diseases or significant comorbidities
Trial design
Design model
Case-control
Time perspective
Cross-sectional
Treatments tested in this trial
Not listed
Trial groups
70 Participants
are grouped into 2 trial groupsGroup A: SLE Patients
Group B: Healthy Controls
Trial outcomes
Primary outcomes
1
Correlation between Blood Indices and SLEDAI -2K score
The primary outcome of this study will be to assess the relationship between lymphocyte-monocyte ratios (LMR), neutrophil-to-lymphocyte ratios (NLR), platelet-to-lymphocyte ratios (PLR), systemic immune-inflammatory index (SIRI) and systemic lupus erythematosus disease activity as measured by the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K). This will involve statistical analysis to determine if there is a significant correlation between these blood indices and the SLEDAI-2K score, indicating their potential utility as biomarkers for SLE activity.
Time frame
1 monthLocations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: